Progress in clinical management of cancer of unknown primary based on molecular testing at 2023 ESMO
Cancer of unknown primary (CUP) is a metastatic syndrome with an unidentifiable primary tumor even after comprehensive clinical and pathological investigations, accounting for approximately 2%-5% of all newly diagnosed cancers. CUP has some common features including aggressiveness, early disseminati...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Editorial Office of China Oncology
2023-11-01
|
| Series: | Zhongguo aizheng zazhi |
| Subjects: | |
| Online Access: | http://www.china-oncology.com/fileup/1007-3639/PDF/1702517906721-283935258.pdf |
| _version_ | 1827345281734148096 |
|---|---|
| author | ZHANG Xiaowei, LIU Xin, LUO Zhiguo |
| author_facet | ZHANG Xiaowei, LIU Xin, LUO Zhiguo |
| author_sort | ZHANG Xiaowei, LIU Xin, LUO Zhiguo |
| collection | DOAJ |
| description | Cancer of unknown primary (CUP) is a metastatic syndrome with an unidentifiable primary tumor even after comprehensive clinical and pathological investigations, accounting for approximately 2%-5% of all newly diagnosed cancers. CUP has some common features including aggressiveness, early dissemination and poor prognosis. With the application of novel molecular tests and drugs, the diagnostic value of gene expression assay and genomic tests in characterizing the molecular features has become increasingly prominent, and new treatment options such as molecular-guided targeted therapy and immunotherapy have become available. This article reviewed the clinical trials of CUP reported at 2023 European Society for Medical Oncology (ESMO) Congress. |
| first_indexed | 2024-03-07T23:04:23Z |
| format | Article |
| id | doaj.art-a3733c25f05840f28cf08bb31c131741 |
| institution | Directory Open Access Journal |
| issn | 1007-3639 |
| language | English |
| last_indexed | 2024-03-07T23:04:23Z |
| publishDate | 2023-11-01 |
| publisher | Editorial Office of China Oncology |
| record_format | Article |
| series | Zhongguo aizheng zazhi |
| spelling | doaj.art-a3733c25f05840f28cf08bb31c1317412024-02-22T06:28:17ZengEditorial Office of China OncologyZhongguo aizheng zazhi1007-36392023-11-01331198999210.19401/j.cnki.1007-3639.2023.11.003Progress in clinical management of cancer of unknown primary based on molecular testing at 2023 ESMOZHANG Xiaowei, LIU Xin, LUO Zhiguo0Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, ChinaCancer of unknown primary (CUP) is a metastatic syndrome with an unidentifiable primary tumor even after comprehensive clinical and pathological investigations, accounting for approximately 2%-5% of all newly diagnosed cancers. CUP has some common features including aggressiveness, early dissemination and poor prognosis. With the application of novel molecular tests and drugs, the diagnostic value of gene expression assay and genomic tests in characterizing the molecular features has become increasingly prominent, and new treatment options such as molecular-guided targeted therapy and immunotherapy have become available. This article reviewed the clinical trials of CUP reported at 2023 European Society for Medical Oncology (ESMO) Congress.http://www.china-oncology.com/fileup/1007-3639/PDF/1702517906721-283935258.pdf|cancer of unknown primary|90-gene expression assay|tissue of origin|site-specific therapy|precision medicine |
| spellingShingle | ZHANG Xiaowei, LIU Xin, LUO Zhiguo Progress in clinical management of cancer of unknown primary based on molecular testing at 2023 ESMO Zhongguo aizheng zazhi |cancer of unknown primary|90-gene expression assay|tissue of origin|site-specific therapy|precision medicine |
| title | Progress in clinical management of cancer of unknown primary based on molecular testing at 2023 ESMO |
| title_full | Progress in clinical management of cancer of unknown primary based on molecular testing at 2023 ESMO |
| title_fullStr | Progress in clinical management of cancer of unknown primary based on molecular testing at 2023 ESMO |
| title_full_unstemmed | Progress in clinical management of cancer of unknown primary based on molecular testing at 2023 ESMO |
| title_short | Progress in clinical management of cancer of unknown primary based on molecular testing at 2023 ESMO |
| title_sort | progress in clinical management of cancer of unknown primary based on molecular testing at 2023 esmo |
| topic | |cancer of unknown primary|90-gene expression assay|tissue of origin|site-specific therapy|precision medicine |
| url | http://www.china-oncology.com/fileup/1007-3639/PDF/1702517906721-283935258.pdf |
| work_keys_str_mv | AT zhangxiaoweiliuxinluozhiguo progressinclinicalmanagementofcancerofunknownprimarybasedonmoleculartestingat2023esmo |